Receive our newsletter – data, insights and analysis delivered to you
July 6, 2009

Caraco Axes Workforce Following FDA Seizure

Caraco Pharmaceutical Laboratories has announced that it will slash around half of its work force to realign expenses after the US Food and Drug Administration (FDA) seized up to 33 of the company's generic drugs due to manufacturing violations. In June 2009 the FDA seized drugs made at t

By cms admin

Caraco Pharmaceutical Laboratories has announced that it will slash around half of its work force to realign expenses after the US Food and Drug Administration (FDA) seized up to 33 of the company’s generic drugs due to manufacturing violations.

In June 2009 the FDA seized drugs made at the company’s Michigan facilities in Detroit, Farmington Hills and Wixom.

Among the drugs were generic versions of heart, pain and psychiatric drugs as well as the epilepsy treatment Tegretol and a generic copy of the diabetes drug Glucophage.

The company will now eliminate around 350 positions, around half of its workforce, after suspending all manufacturing until talks are concluded with the FDA.

According to the Wall Street Journal shares in Caraco have fallen 3.2% to $3.05.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU